The
recombinant DNA technology has revolutionized the field of molecular biology.
重组DNA技术彻底改变了分子生物学领域。
Scientists successfully created a
recombinant vaccine by combining parts of different virus strains.
科学家成功通过组合不同病毒株的部分片段制造出了一种重组疫苗。
This
recombinant protein is used in clinical trials to treat a rare genetic disorder.
这种重组蛋白质在临床试验中被用于治疗一种罕见的遗传疾病。
Recombinant insulin, produced in bacteria, has been crucial for treating diabetes.
在细菌中生产的重组胰岛素对糖尿病的治疗至关重要。
The expression of the
recombinant gene was confirmed through a series of biochemical assays.
通过一系列生化实验确认了重组基因的表达。
Using
recombinant techniques, we can insert a human gene into the genome of an animal model.
利用重组技术，我们可以将人源基因插入动物模型的基因组中。
The
recombinant plasmid was introduced into mammalian cells for further study.
重组质粒被导入哺乳动物细胞以进行进一步研究。
Researchers were able to isolate and purify the
recombinant enzyme from the cell culture.
研究人员能够从细胞培养物中分离并纯化出重组酶。
A
recombinant form of the hormone was synthesized in order to enhance its stability and effectiveness.
为了提高其稳定性和有效性，研究人员合成了该激素的重组形式。
The development of
recombinant growth factors has greatly advanced tissue engineering research.
重组生长因子的发展极大地推动了组织工程学的研究。
Another set of systems can effectively support production not only in traditional areas such as antibodies, vaccines, recombinant proteins and blood products but also for emerging therapeutics like plasmids, viral vectors and nucleic acids.
另一套系统不仅可以有效支持抗体、疫苗、重组蛋白和血液制品等传统领域的生产，还可以有效支持质粒、病毒载体和核酸等新兴疗法的生产。
Coincidentally, after Japanese cosmetics company Shiseido established its fund company in China in May 2022, the first enterprise that it invested in was Jiangsu Trautec Medical Technology Co Ltd, a local company that focuses on the development and production of recombinant collagen-based biomaterials.
无独有偶，日本化妆品公司资生堂于2022年5月在中国成立基金公司后，其投资的第一家企业是江苏特劳泰克医疗技术有限公司，这是一家专注于开发和生产重组胶原蛋白生物材料的本土公司。
In January 2022, the National Medical Products Administration issued an industrial standard for recombinant collagen, a subcategory of collagen that is widely used in the medical aesthetics sector, specifying its quality control requirements, test indicators, test methods and biological evaluation.
2022年1月，国家医疗产品管理局发布了重组胶原蛋白的行业标准，明确了其质量控制要求、检测指标、检测方法和生物评价。
In December, the NMPA launched a set of standards, further clarifying the evaluation process of recombinant collagen for medical aesthetics use.
12月，NMPA推出了一套标准，进一步明确了用于医学美学用途的重组胶原蛋白的评估过程。
With over 30 years of development, enterprises had broken the technical barrier of producing recombinant collagen, and the sector has witnessed explosive growth.
经过30多年的发展，企业突破了生产重组胶原蛋白的技术壁垒，该行业实现了爆炸式增长。
Sinopharm is the only enterprise in the world to have independently developed four COVID-19 vaccines via three technical platforms－two inactivated vaccines, one genetic recombinant vaccine and one mRNA vaccine.
国药集团是世界上唯一一家通过三个技术平台自主研发4种新冠肺炎疫苗的企业——两种灭活疫苗、一种基因重组疫苗和一种mRNA疫苗。
Sinopharm is the only enterprise in the world that has independently developed four COVID-19 vaccines via three technical platforms -- two inactivated vaccines, one genetic recombinant vaccine and one mRNA vaccine.
国药集团是全球唯一一家通过两种灭活疫苗、一种基因重组疫苗和一种mRNA疫苗三大技术平台自主研发四种新冠肺炎疫苗的企业。
Beijing-based YishengBio Co Ltd announced during the fair that its PIKA recombinant COVID-19 vaccine, an innovative prophylactic and therapeutic vaccine candidate against multiple SARS-CoV-2 variants, has won clinical trial approval from health authorities in the United Arab Emirates to treat patients with mild to moderate SARS-CoV-2 infections.
在北京举行的展览期间，总部位于北京的YishengBio公司宣布，其PIKA重组COVID-19疫苗，一种针对多种SARS-CoV-2变异株的创新预防和治疗性疫苗候选产品，已获得阿联酋卫生当局的临床试验批准，用于治疗轻度至中度SARS-CoV-2感染的患者。
The agreements said YishengBio will conduct clinical trials in the UAE and Serbia for its PIKA recombinant vaccine for both COVID-19 prevention and treatment.
根据协议,YishengBio(亦称"谊生源")将在阿联酋和塞尔维亚开展PIKA重组新冠疫苗的临床试验,该疫苗将用于预防和治疗COVID-19。
The bioscience subsidiary of State-owned healthcare company Sinopharm, CNBG has been conducting research and development in different types of COVID-19 vaccines via inactivated, recombinant and mRNA technologies.
国药集团旗下的生物科学子公司CNBG一直在通过灭活、重组和mRNA技术研究和开发不同类型的COVID-19疫苗。这里将英文句子翻译成
According to Chen, the company's recombinant vaccine candidate has finished first and second-phase clinical trials in China with favorable results.
据陈说，公司的重组疫苗候选产品在中国已完成第一和第二阶段临床试验，结果良好。
That includes the updated versions of its two approved inactivated vaccines, two vaccine candidates under development via recombinant and mRNA technologies, and three test kits.
这包括其两款获批的灭活疫苗的更新版本，以及通过重组技术和mRNA技术开发的两种候选疫苗，还有三款检测试剂盒。
Clover Biopharmaceuticals, a global clinical-stage biotechnology company, announced on Tuesday the completion of targeted enrollment of adult and elderly participants in the Spectra project, or the Study Evaluating Protective-Efficacy and Safety of Clover's Trimeric Recombinant Protein-based and Adjuvanted COVID-19 Vaccine.
全球临床阶段生物技术公司Clover Biopharmaceuticals周二宣布，已完成Spectra项目的目标成人和老年人参与者招募，该项目即评估Clover基于三聚体重组蛋白和佐剂的COVID-19疫苗保护效力和安全性的研究。
Zheng Chunyang, president of Robustnique Co, another homegrown cosmetic producer based in Tianjin, which makes recombinant enzymes and high-end cosmetics products, said most of the new ingredients required for cosmetics production in China need to comply with the Inventory of Existing Cosmetic Ingredients.
Last month, Chinese authorities approved clinical trials for a recombinant vaccine candidate by the Academy of Military Sciences of the People's Liberation Army and Chinese biotech firm CanSino Bio.
CanSino Bio announced last week that the vaccine, produced through recombinant DNA technology, would start Phase 2 clinical trials soon.
The National Vaccine and Serum Institute, an affiliate of CNBG that is developing a genetically engineered vaccine for the virus, has completed the gene sequence synthesis, and is taking the next steps, including construction of a recombinant plasmid and selection of engineering bacteria.
The National Vaccine & Serum Institute, an affiliate to CNBG that is developing a genetically engineered vaccine for the virus, has completed the gene sequence synthesis, and is taking the next steps including construction of recombinant plasmid and selection of engineering bacteria.
China National Pharmaceutical Group Co Ltd, or Sinopharm, announced recently it had developed four Omicron-specific vaccine candidates, including inactivated, recombinant protein, and mRNA varieties, as well as an inhalable monoclonal antibody for COVID-19 prevention.
For the Omicron XBB.1.5 recombinant variant, which has been raising concerns globally, Meinian OneHealth said that it is expected to launch physical exams related to the digestive system, which the XBB variant is said to possibly attack.
An industrial base dedicated to precision medicines with a total investment of 1.15 billion yuan by Obio Technology (Shanghai) Corp Ltd－a high-tech enterprise specializing in basic life sciences research, gene therapy drug incubation and clinical-grade recombinant viruses－also recently launched construction at a biomedical industrial park in Lingang New Area at Shanghai Pilot Free Trade Zone.
Obio Technology (Shanghai) Corp Ltd，一家专注于基础生命科学研究、基因治疗药物孵化和临床级重组病毒的高科技企业，最近也在上海自由贸易试验区临港新区的一个生物医药工业园区启动了一个总投资11.5亿元的精密药物工业基地的建设。
Yang Xiaoming, president of CNBG, said that currently, there are more than 100 research institutions worldwide working on vaccines targeting COVID-19, and the vaccines can be classified into roughly five types－inactivated vaccine, gene recombinant vaccine, adenovirus vaccine, viral vector vaccine, and nucleic acid vaccine.
The exhibits will range from biological materials, biological enzymes, recombinant proteins, and blood products to new biological vaccines, therapeutic antibodies, transgenic mouse platforms, antibody technology service platforms, and data system development platforms, to help solve challenges facing pharmaceutical and biotechnological companies in product promotion, technological innovation, process optimization and industrial solutions, which will help accelerate the transformation and upgrading of the Chinese pharmaceutical industry, she said.
Zheng Chunyang, president of the Robustnique Co, which is committed to developing recombinant enzymes and high-end cosmetics, said currently new ingredients for cosmetics production in China must comply with the Inventory of Existing Cosmetic Ingredients.
Chen Wei, a military biomedical expert and academician at the Chinese Academy of Engineering who landed on the list this year, leads a team to work with CanSino Biologics Inc in developing a recombinant vaccine requiring only one shot which has conditional market approval.